--- title: "BioLineRx (BLRX.US) — 财务报表" type: "Symbol" locale: "zh-CN" url: "https://longbridge.com/zh-CN/quote/BLRX.US/norm.md" symbol: "BLRX.US" name: "BioLineRx" parent: "https://longbridge.com/zh-CN/quote/BLRX.US.md" datetime: "2026-05-19T17:32:24.781Z" locales: - [en](https://longbridge.com/en/quote/BLRX.US/norm.md) - [zh-CN](https://longbridge.com/zh-CN/quote/BLRX.US/norm.md) - [zh-HK](https://longbridge.com/zh-HK/quote/BLRX.US/norm.md) --- # BioLineRx (BLRX.US) — 财务报表 ## 利润表 (USD) | 指标 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | | --- | --- | --- | --- | --- | --- | | 每股收益 | -0.3120 | -0.2244 | -0.9972 | 1.39 | -1.46 | | ROE | -29.37% | -19.73% | -77.00% | 119.50% | -116.07% | | 营业收入 | 194000.00 | 427000.00 | 304000.00 | 255000.00 | 11.75M | | 净利润 | -1.39M | -977000.00 | -3.94M | 5.13M | -3.19M | | 营业利润 | -3.39M | -2.21M | -2.30M | -2.39M | -3.17M | | 毛利率 | 79.38% | 80.33% | 76.32% | 86.67% | 48.17% | | 净利率 | -713.92% | -228.81% | -1296.05% | 2010.59% | -27.13% | | 利润含金量 | - | - | - | - | - | ## 资产负债表 (USD) | 指标 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | | --- | --- | --- | --- | --- | --- | | 资产与负债 | 40.91M | 39.80M | 43.27M | 43.51M | 38.91M | | 权益乘数 | 1.75 | 2.04 | 2.16 | 2.09 | 2.89 | | 每股净资产 | 4.18 | 4.49 | 4.71 | 5.61 | 6.04 | | 资产周转率 | 0.0296 | 0.2752 | 0.3199 | 0.4698 | 0.5629 | | 现金及短投 | 20.88M | 25.21M | 28.16M | 26.37M | 19.56M | | 存货与应收 | 2.15M | 2.18M | 2.85M | 3.31M | 3.15M | | 长期投资 | 856000.00 | 892000.00 | 997000.00 | 1.16M | 1.35M | | 净债务 | -10.73M | -13.83M | -15.56M | -12.63M | -4.52M | ## 现金流量表 (USD) | 指标 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | | --- | --- | --- | --- | --- | --- | | 经营现金流 | -3.20M | -2.11M | -177000.00 | -2.59M | -8.61M | | 投资现金流 | -337000.00 | 3.67M | -3.70M | -8.18M | 11.16M | | 融资现金流 | -1.25M | -916000.00 | 1.60M | 9.45M | -1.11M | | 自由现金流 | -3.01M | -2.57M | 2.27M | 61625.00 | -3.34M | | 现金流充裕率 | -250.59% | -167.68% | -14.10% | -207.78% | -71.17% | | 举债与偿债 | - | - | - | - | 0.0000 | | 资本支出 | -25000.00 | - | - | - | 6000.00 |